October 23, 2018
1 min read

Carl Zeiss Meditec acquires miLOOP developer IanTECH

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Carl Zeiss Meditec will acquire IanTECH, the developer of the miLOOP lens fragmentation device, expanding its cataract surgery portfolio, the company announced in a press release.

“We expect that IanTECH will complement our leading portfolio of equipment and consumables in cataract surgery, allowing us to offer physicians and patients a new standard of care,” Zeiss President and CEO Ludwin Monz, PhD, said in the release. “The technology has the potential to simplify challenging cases, reduce risk to patients and further improve outcomes while being easy to train and adapt for surgeons.”

IanTECH, headquartered in Reno, Nevada, focuses on micro-interventional cataract surgery technology.

“I think there is a shared vision that cataract surgery had seen only incremental innovation with phacoemulsification, which more or less has been the same for the last 50 years,” IanTECH co-founder Sean Ianchulev, MD, MPH, told Healio.com/OSN.

With micro-interventional technology, including the miLOOP, surgeons “can shift the entire paradigm and really create a completely different approach, really optimizing the surgical technique and delivering potentially better outcomes and procedures in the future,” he added.


Disclosure: Ianchulev reports he is the founder and chairman of the board for IanTECH.

Editor’s note: This article was updated to include statements from Sean Ianchulev.